Article Information
History
- December 11, 2020.
Article Versions
- Version 1 (November 20, 2020 - 06:19).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Debra Van Egeren§,1,2,3,
- Alexander Novokhodko§,4,
- Madison Stoddard§,5,
- Uyen Tran5,
- Bruce Zetter1,3,
- Michael Rogers1,3,
- Bradley L. Pentelute6,
- Jonathan M. Carlson7,
- Mark Hixon8,
- Diane Joseph-McCarthy9 and
- Arijit Chakravarty5,*
- 1Harvard Medical School, Boston, MA, USA
- 2Dana-Farber Cancer Institute, Boston, MA, USA
- 3Boston Children’s Hospital, Boston, MA, USA
- 4University of Washington, Seattle, WA, USA
- 5Fractal Therapeutics, Cambridge, MA, USA
- 6Massachusetts Institute of Technology, Cambridge, MA, USA
- 7Microsoft Research, Redmond, WA, USA
- 8Mark S. Hixon Consulting, LLC, San Diego, CA, USA
- 9Boston University, Boston, MA, USA
- ↵*Corresponding author, email: arijit{at}fractaltx.com
↵§ Contributed equally
Posted December 11, 2020.
Risk of evolutionary escape from neutralizing antibodies targeting SARS-CoV-2 spike protein
